Personalization of Induction Therapy for Pediatric AML to Ara-C plus Dauno plus Etoposide (ADE) or Clofarabine plus Ara-C According to a Polygenic Ara-C SNP Score-ACS10

被引：0
|
作者：
Lamba, Jatinder K. [1 ,2 ]
Marrero, Richard J. [3 ]
Elsayed, Abdelrahman H. [3 ]
Cao, Xueyuan [4 ]
Wu, Huiyun [5 ]
Inaba, Hiroto [6 ]
Raimondi, Susana C. [7 ]
Pui, Ching-Hon [8 ]
Ribeiro, Raul C. [9 ]
Rubnitz, Jeffrey E. [6 ]
Pounds, Stanley B. [5 ]
机构：
[1] Univ Florida, Coll Pharm Pharmacotherapy & Translat Re, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA
[2] UF Hlth Canc Ctr, Gainesville, FL USA
[3] Univ Florida, Dept Pharmacotherapy & Translat Res, Coll Pharm, Gainesville, FL USA
[4] Univ Tennessee, Dept Hlth Promot & Dis Prevent, Hlth Sci Ctr, Memphis, TN USA
[5] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN USA
[6] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA
[7] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN USA
[8] St Jude Childrens Rsch Hosp, Dept Oncol, Memphis, TN USA
[9] 5t Jude Childrens Res Hosp, Memphis, TN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159657
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1039 / 1040
页数：2
相关论文
共 50 条
  • [1] Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
    Brunnberg, U.
    Mohr, M.
    Noppeney, R.
    Duerk, H. A.
    Sauerland, M. C.
    Mueller-Tidow, C.
    Krug, U.
    Koschmieder, S.
    Kessler, T.
    Mesters, R. M.
    Schulz, C.
    Kosch, M.
    Buechner, T.
    Ehninger, G.
    Duehrsen, U.
    Serve, H.
    Berdel, W. E.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 990 - 996
  • [2] CCNU PLUS CYTOSINE-ARABINOSIDE (ARA-C) TREATMENT OF ACUTE MYELOCYTIC LEUKEMIA COMPARED WITH THIOGUANINE (TG) PLUS ARA-C
    WALLACE, HJ
    HOAGLAND, HC
    ELLISON, RR
    GLIDEWELL, O
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1973, 14 (MAR): : 100 - +
  • [3] Induction Therapy by Ara-C Plus Daunorubicin Versus Ara-C plus Gemtuzumab Ozogamicin: Interim Analysis of a Randomized Phase II Trial of the SAL In Elderly Patients with Acute Myeloid Leukemia
    Brunnberg, Uta
    Mohr, Michael
    Noppeney, Richard
    Duerk, Heinz A.
    Sauerland, Maria Cristina
    Mueller-Tidow, Carsten
    Krug, Utz O.
    Koschmieder, Steffen
    Kessler, Torsten
    Mesters, Rolf M.
    Schulz, Christiane
    Buchner, Thomas
    Ehninger, Gerhard
    Duehrsen, Ulrich
    Serve, Hubert
    Berdel, Wolfgang E.
    BLOOD, 2010, 116 (21) : 152 - 152
  • [4] ARA-C SNP SCORE AS A PREDICTIVE TOOL OF AML TREATMENT OUTCOME.
    Elsayed, A.
    Cao, X.
    Rubnitz, J.
    Ribeiro, R.
    Pounds, S.
    Lamba, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S119 - S119
  • [5] ARA-C SNP SCORE AS A PREDICTIVE TOOL OF AML TREATMENT OUTCOME.
    Elsayed, A.
    Cao, X.
    Rubnitz, J.
    Ribeiro, R.
    Pounds, S.
    Lamba, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S24 - S24
  • [6] Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).
    Beran, H
    Giles, FJ
    Cortes, JE
    Thomas, DA
    Koller, C
    O'Brien, SM
    Keating, MJ
    Freireich, E
    Kantarjian, HM
    Estey, E
    BLOOD, 1999, 94 (10) : 226B - 226B
  • [7] SUBSEQUENT HSCT IN THE CLASSIC I STUDY ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY AML AFTER CLO plus ARA-C OR ARA-C ALONE: A LANDMARK ANALYSIS
    Ganguly, S.
    Kantarjian, H.
    Wetzler, M.
    Rizzieri, D.
    Schiller, G.
    Jagasia, M.
    Stuart, R.
    Avigan, D.
    Craig, M.
    Collins, R.
    Maris, M.
    Kovacsovics, T.
    Goldberg, S.
    Seiter, K.
    Hari, P.
    Greiner, J.
    Vey, N.
    Recher, C.
    Ravandi, F.
    Wang, E.
    Johns, D.
    Partisano, A.
    Faderl, S.
    HAEMATOLOGICA, 2012, 97 : 32 - 32
  • [8] Treatment of de novo acute myelogenous leukemia (AML) with liposomal doxorubicin plus Ara-C
    Sanchez, BO
    Gonzalez, GA
    Cortes, J
    BLOOD, 2002, 100 (11) : 269B - 269B
  • [9] Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim
    Tang, Yongmin
    Li, Lixia
    Wang, Di
    Shen, Hongqiang
    Qian, Baiqin
    Luo, Chunfang
    Zhang, Haizhong
    BLOOD, 2007, 110 (11) : 114B - 114B
  • [10] Idarubicin and standard dose ARA-C (I plus A) for refractory and relapsed adult
    Novik, Y
    Paietta, E
    Dutcher, JP
    Wiernik, PH
    BLOOD, 1999, 94 (10) : 234B - 235B
12345